DexCom Inc Net Income
| DXCM Stock | USD 71.63 0.90 1.24% |
As of the 4th of February, DexCom shows the Mean Deviation of 1.66, downside deviation of 3.46, and Coefficient Of Variation of 2395.21. DexCom Inc technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm DexCom Inc jensen alpha, potential upside, as well as the relationship between the Potential Upside and skewness to decide if DexCom Inc is priced favorably, providing market reflects its regular price of 71.63 per share. Given that DexCom has jensen alpha of 0.072, we urge you to verify DexCom Inc's prevailing market performance to make sure the company can sustain itself at a future point.
DexCom Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 6.1428 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 662.6 M | 695.8 M | |
| Net Income From Continuing Ops | 662.6 M | 695.8 M | |
| Net Income Applicable To Common Shares | 392.4 M | 412 M | |
| Net Income Per Share | 1.28 | 1.35 | |
| Net Income Per E B T | 0.73 | 0.77 |
DexCom | Net Income | Build AI portfolio with DexCom Stock |
Evaluating DexCom's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into DexCom Inc's fundamental strength.
Latest DexCom's Net Income Growth Pattern
Below is the plot of the Net Income of DexCom Inc over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in DexCom Inc financial statement analysis. It represents the amount of money remaining after all of DexCom Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is DexCom's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 576.2 M | 10 Years Trend |
|
Net Income |
| Timeline |
DexCom Net Income Regression Statistics
| Arithmetic Mean | 186,645,912 | |
| Coefficient Of Variation | 158.83 | |
| Mean Deviation | 261,325,896 | |
| Median | (3,965,000) | |
| Standard Deviation | 296,454,697 | |
| Sample Variance | 87885.4T | |
| Range | 822.9M | |
| R-Value | 0.87 | |
| Mean Square Error | 23474.1T | |
| R-Squared | 0.75 | |
| Slope | 50,827,804 | |
| Total Sum of Squares | 1406166.2T |
DexCom Net Income History
Other Fundumenentals of DexCom Inc
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
DexCom Net Income component correlations
DexCom Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for DexCom is extremely important. It helps to project a fair market value of DexCom Stock properly, considering its historical fundamentals such as Net Income. Since DexCom's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of DexCom's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of DexCom's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Health Care Equipment & Supplies sector continue expanding? Could DexCom diversify its offerings? Factors like these will boost the valuation of DexCom. Projected growth potential of DexCom fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DexCom data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.099 | Earnings Share 1.8 | Revenue Per Share | Quarterly Revenue Growth 0.216 | Return On Assets |
Understanding DexCom Inc requires distinguishing between market price and book value, where the latter reflects DexCom's accounting equity. The concept of intrinsic value - what DexCom's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push DexCom's price substantially above or below its fundamental value.
It's important to distinguish between DexCom's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DexCom should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, DexCom's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
DexCom 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to DexCom's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of DexCom.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in DexCom on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding DexCom Inc or generate 0.0% return on investment in DexCom over 90 days. DexCom is related to or competes with STERIS Plc, Insulet, Zimmer Biomet, Koninklijke Philips, Smith Nephew, Laboratory, and Waters. DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose ... More
DexCom Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure DexCom's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess DexCom Inc upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.46 | |||
| Information Ratio | 0.0219 | |||
| Maximum Drawdown | 14.66 | |||
| Value At Risk | (2.87) | |||
| Potential Upside | 3.31 |
DexCom Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for DexCom's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as DexCom's standard deviation. In reality, there are many statistical measures that can use DexCom historical prices to predict the future DexCom's volatility.| Risk Adjusted Performance | 0.0379 | |||
| Jensen Alpha | 0.072 | |||
| Total Risk Alpha | (0.06) | |||
| Sortino Ratio | 0.017 | |||
| Treynor Ratio | 0.147 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of DexCom's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
DexCom February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0379 | |||
| Market Risk Adjusted Performance | 0.157 | |||
| Mean Deviation | 1.66 | |||
| Semi Deviation | 3.26 | |||
| Downside Deviation | 3.46 | |||
| Coefficient Of Variation | 2395.21 | |||
| Standard Deviation | 2.68 | |||
| Variance | 7.16 | |||
| Information Ratio | 0.0219 | |||
| Jensen Alpha | 0.072 | |||
| Total Risk Alpha | (0.06) | |||
| Sortino Ratio | 0.017 | |||
| Treynor Ratio | 0.147 | |||
| Maximum Drawdown | 14.66 | |||
| Value At Risk | (2.87) | |||
| Potential Upside | 3.31 | |||
| Downside Variance | 12.0 | |||
| Semi Variance | 10.6 | |||
| Expected Short fall | (1.51) | |||
| Skewness | (2.42) | |||
| Kurtosis | 13.65 |
DexCom Inc Backtested Returns
DexCom appears to be very steady, given 3 months investment horizon. DexCom Inc secures Sharpe Ratio (or Efficiency) of 0.19, which denotes the company had a 0.19 % return per unit of risk over the last 3 months. We have found twenty-seven technical indicators for DexCom Inc, which you can use to evaluate the volatility of the firm. Please utilize DexCom's Coefficient Of Variation of 2395.21, downside deviation of 3.46, and Mean Deviation of 1.66 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, DexCom holds a performance score of 15. The firm shows a Beta (market volatility) of 0.69, which means possible diversification benefits within a given portfolio. As returns on the market increase, DexCom's returns are expected to increase less than the market. However, during the bear market, the loss of holding DexCom is expected to be smaller as well. Please check DexCom's potential upside, as well as the relationship between the skewness and day typical price , to make a quick decision on whether DexCom's price patterns will revert.
Auto-correlation | 0.87 |
Very good predictability
DexCom Inc has very good predictability. Overlapping area represents the amount of predictability between DexCom time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of DexCom Inc price movement. The serial correlation of 0.87 indicates that approximately 87.0% of current DexCom price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.87 | |
| Spearman Rank Test | 0.86 | |
| Residual Average | 0.0 | |
| Price Variance | 6.23 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
DexCom Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, DexCom Inc reported net income of 576.2 M. This is 68.83% higher than that of the Health Care Equipment & Supplies sector and 141.99% higher than that of the Health Care industry. This indicator is about the same for all United States stocks average (which is currently at 5.7097980139E8).
DexCom Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DexCom's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DexCom could also be used in its relative valuation, which is a method of valuing DexCom by comparing valuation metrics of similar companies.DexCom is currently under evaluation in net income category among its peers.
DexCom ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, DexCom's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to DexCom's managers, analysts, and investors.Environmental | Governance | Social |
DexCom Institutional Holders
Institutional Holdings refers to the ownership stake in DexCom that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of DexCom's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing DexCom's value.| Shares | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 5.6 M | Capital Research Global Investors | 2025-06-30 | 5.4 M | Norges Bank | 2025-06-30 | 5.2 M | Amvescap Plc. | 2025-06-30 | 5 M | Amundi | 2025-06-30 | 4.4 M | Groupama Asset Management | 2025-06-30 | 4 M | American Century Companies Inc | 2025-06-30 | 3.9 M | Bank Of New York Mellon Corp | 2025-06-30 | 3.9 M | Northern Trust Corp | 2025-06-30 | 3.8 M | Vanguard Group Inc | 2025-06-30 | 48.3 M | Blackrock Inc | 2025-06-30 | 39 M |
DexCom Fundamentals
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.0702 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 27.74 B | ||||
| Shares Outstanding | 390.02 M | ||||
| Shares Owned By Insiders | 0.41 % | ||||
| Shares Owned By Institutions | 97.19 % | ||||
| Number Of Shares Shorted | 15.46 M | ||||
| Price To Earning | 245.31 X | ||||
| Price To Book | 10.45 X | ||||
| Price To Sales | 6.22 X | ||||
| Revenue | 4.03 B | ||||
| Gross Profit | 2.66 B | ||||
| EBITDA | 945.7 M | ||||
| Net Income | 576.2 M | ||||
| Cash And Equivalents | 2.37 B | ||||
| Cash Per Share | 6.14 X | ||||
| Total Debt | 2.59 B | ||||
| Debt To Equity | 1.17 % | ||||
| Current Ratio | 3.77 X | ||||
| Book Value Per Share | 6.99 X | ||||
| Cash Flow From Operations | 989.5 M | ||||
| Short Ratio | 3.13 X | ||||
| Earnings Per Share | 1.80 X | ||||
| Price To Earnings To Growth | 1.02 X | ||||
| Target Price | 85.19 | ||||
| Number Of Employees | 10.2 K | ||||
| Beta | 1.49 | ||||
| Market Capitalization | 28.09 B | ||||
| Total Asset | 6.48 B | ||||
| Retained Earnings | 1.6 B | ||||
| Working Capital | 1.37 B | ||||
| Current Asset | 231.3 M | ||||
| Current Liabilities | 66.9 M | ||||
| Net Asset | 6.48 B |
About DexCom Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DexCom Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DexCom using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DexCom Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Will Health Care Equipment & Supplies sector continue expanding? Could DexCom diversify its offerings? Factors like these will boost the valuation of DexCom. Projected growth potential of DexCom fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DexCom data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.099 | Earnings Share 1.8 | Revenue Per Share | Quarterly Revenue Growth 0.216 | Return On Assets |
Understanding DexCom Inc requires distinguishing between market price and book value, where the latter reflects DexCom's accounting equity. The concept of intrinsic value - what DexCom's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push DexCom's price substantially above or below its fundamental value.
It's important to distinguish between DexCom's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DexCom should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, DexCom's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.